Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.60 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | PLA2G7 | Q13093 | 3/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12009180 | 0.84 | CYP11B1 (0.48) | CALM1CYP11B1CYP11B2ATMPLA2G7 | |
| SCHEMBL24769738 | 0.81 | CYP1A2 (0.54) | CYP11B1CYP11B2HRH3TBXAS1 | |
| SCHEMBL28544958 | 0.80 | CALM1 (0.60) | CALM1CYP11B1CYP11B2TAAR1HRH3 | |
| SCHEMBL28966772 | 0.80 | TAAR1 (0.50) | CYP11B1CYP11B2ATMTAAR1HRH3 | |
| SCHEMBL28193213 | 0.80 | CYP11B1 (0.48) | CYP11B1CYP11B2HRH3CYP19A1 | |
| SCHEMBL2718124 | 0.79 | CYP11B1 (0.67) | CYP11B1CYP11B2ATM | |
| SCHEMBL177863 | 0.78 | CYP11B1 (0.65) | CALM1CYP11B1CYP11B2HRH3TBXAS1 | |
| SCHEMBL29995759 | 0.78 | CYP11B1 (0.65) | CALM1CYP11B1CYP11B2HRH3TBXAS1 | |
| Diphenylmethane SCHEMBL14763944 | 0.78 | CALM1 (1.00) | CALM1LTA4HIDH1 | |
| Diphenylmethane SCHEMBL4361124 | 0.78 | CALM1 (1.00) | CALM1LTA4HIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | claimed |
| US-20180235993-A1 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES | IDENIX PHARMACEUTICALS LLC (US) | 2018-08-23 | — | — | US | claimed |
| US-9968628-B2 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS LLC (US) | 2018-05-15 | — | — | US | claimed |
| EP-1534255-B1 | PROCESSES FOR PREPARING 1,3-DIOXOLANE NUCLEOSIDES | PHARMASSET INC (US) | 2011-01-19 | — | — | EP | claimed |
| US-7230100-B2 | Stereoselective method for the preparation of nucleosides | SHIRE BIOCHEM., INC. (CA) | 2007-06-12 | — | — | US | claimed |
| US-7109334-B2 | Stereoselective methods for the preparation of nucleosides | SHIRE BIOCHEM, INC. (CA) | 2006-09-19 | — | — | US | claimed |
| US-5248776-A | Multistage reaction with sulfiding, cyclization and oxidative cleavage | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1993-09-28 | — | — | US | claimed |
| WO-1992010496-A1 | ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-06-25 | — | — | WO | claimed |
| US-20250340584-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-11-06 | — | — | US | disclosed |
| EP-3351548-B1 | CROSSLINKED NUCLEIC ACID GUNA, METHOD FOR PRODUCING SAME, AND INTERMEDIATE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2025-08-20 | — | — | EP | disclosed |
| US-12338265-B2 | Crosslinked artificial nucleic acid ALNA | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-06-24 | — | — | US | disclosed |
| CN-120152976-A | Anti-coronavirus compounds, compositions and uses thereof | 上海柯君医药科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-113549120-B | Method for preparing ribonucleoside | 吉利德科学公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-108348526-B | Methods of treating arenaviridae and coronaviridae viral infections | 吉利德科学公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-1992010496-A1 | ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-06-25 | — | — | WO | disclosed |
| US-4386084-A | BACTERICIDES; SULFONAMIDE POTENTIATION | BASF AKTIENGESELLSCHAFT (DE) | 1983-05-31 | — | — | US | disclosed |
| EP-0053695-A2 | Esters of N-pyrimidinyl-carbamic acid, method of preparing them and pharmaceutical compositions containing them | BASF Aktiengesellschaft (DE) | 1982-06-16 | — | — | EP | disclosed |
| US-4273931-A | Reduction of alkyl esters of carbonic-carboxylic anhydrides to alcohols | ISTITUTO CHEMIOTERAPICO ITALIANO, S.P.A. (IT) | 1981-06-16 | — | — | US | disclosed |
| EP-0001633-A1 | Processes for preparing tri-heterocyclic substituted methanes and their conversion into further intermediates useful in the preparation of pharmacologically active compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-05-02 | — | — | EP | disclosed |
| US-4052553-A | BACTERICIDE, ANTIMALARIAL | BURROUGHS WELLCOME CO. (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235993-A1 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES | MTAP, PHOSPHO1, PNP | CALM1 1991/4885CYP11B1 474/4885CYP11B2 528/4885 |
| US-20250340584-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | POLN, DDX21, MUS81 | CALM1 2054/4885CYP11B1 4093/4885CYP11B2 4439/4885 |
| US-12338265-B2 | Crosslinked artificial nucleic acid ALNA | POLN, DDX21, MUS81 | CALM1 2054/4885CYP11B1 4093/4885CYP11B2 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.